Theranexus Updates Cash Position and Strategic Focus

Theranexus SA (FR:ALTHX) has released an update.

Theranexus reports a slight increase in cash reserves to €1.9 million as of September 30, 2024, aided by a significant research tax credit. The company remains focused on advancing its treatments for rare neurological diseases, aiming to register its liquid miglustat formulation in Europe and initiate a phase 3 trial for Batten disease.

For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.